These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
127 related articles for article (PubMed ID: 9000657)
1. A phase I trial of humanized anti-interleukin 2 receptor antibody in renal transplantation. Vincenti F; Lantz M; Birnbaum J; Garovoy M; Mould D; Hakimi J; Nieforth K; Light S Transplantation; 1997 Jan; 63(1):33-8. PubMed ID: 9000657 [TBL] [Abstract][Full Text] [Related]
2. Treatment of acute graft-versus-host disease with humanized anti-Tac: an antibody that binds to the interleukin-2 receptor. Anasetti C; Hansen JA; Waldmann TA; Appelbaum FR; Davis J; Deeg HJ; Doney K; Martin PJ; Nash R; Storb R Blood; 1994 Aug; 84(4):1320-7. PubMed ID: 8049447 [TBL] [Abstract][Full Text] [Related]
3. Anti-interleukin-2 receptor antibodies for the prevention of rejection in pediatric renal transplant patients: current status. Swiatecka-Urban A Paediatr Drugs; 2003; 5(10):699-716. PubMed ID: 14510627 [TBL] [Abstract][Full Text] [Related]
5. Randomized controlled trial of a monoclonal antibody against the interleukin-2 receptor (33B3.1) as compared with rabbit antithymocyte globulin for prophylaxis against rejection of renal allografts. Soulillou JP; Cantarovich D; Le Mauff B; Giral M; Robillard N; Hourmant M; Hirn M; Jacques Y N Engl J Med; 1990 Apr; 322(17):1175-82. PubMed ID: 2157982 [TBL] [Abstract][Full Text] [Related]
6. Disposition of basiliximab, an interleukin-2 receptor monoclonal antibody, in recipients of mismatched cadaver renal allografts. Kovarik J; Wolf P; Cisterne JM; Mourad G; Lebranchu Y; Lang P; Bourbigot B; Cantarovich D; Girault D; Gerbeau C; Schmidt AG; Soulillou JP Transplantation; 1997 Dec; 64(12):1701-5. PubMed ID: 9422405 [TBL] [Abstract][Full Text] [Related]
8. Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. Daclizumab Triple Therapy Study Group. Vincenti F; Kirkman R; Light S; Bumgardner G; Pescovitz M; Halloran P; Neylan J; Wilkinson A; Ekberg H; Gaston R; Backman L; Burdick J N Engl J Med; 1998 Jan; 338(3):161-5. PubMed ID: 9428817 [TBL] [Abstract][Full Text] [Related]
9. Immunoprophylaxis with basiliximab, a chimeric anti-interleukin-2 receptor monoclonal antibody, in combination with azathioprine-containing triple therapy in liver transplant recipients. Calmus Y; Scheele JR; Gonzalez-Pinto I; Jaurrieta EJ; Klar E; Pageaux GP; Scudamore CH; Cuervas-Mons V; Metselaar HJ; Prestele H; Girault D Liver Transpl; 2002 Feb; 8(2):123-31. PubMed ID: 11862588 [TBL] [Abstract][Full Text] [Related]
10. Murine OKT4A immunosuppression in cadaver donor renal allograft recipients: a cooperative clinical trials in transplantation pilot study. Cooperative Clinical Trials in Transplantation Research Group. Transplantation; 1997 May; 63(9):1243-51. PubMed ID: 9158016 [TBL] [Abstract][Full Text] [Related]
11. Reduced immunogenicity and improved pharmacokinetics of humanized anti-Tac in cynomolgus monkeys. Hakimi J; Chizzonite R; Luke DR; Familletti PC; Bailon P; Kondas JA; Pilson RS; Lin P; Weber DV; Spence C J Immunol; 1991 Aug; 147(4):1352-9. PubMed ID: 1869828 [TBL] [Abstract][Full Text] [Related]
12. New monoclonal antibodies in renal transplantation. Vincenti F Minerva Urol Nefrol; 2003 Mar; 55(1):57-66. PubMed ID: 12773967 [TBL] [Abstract][Full Text] [Related]
13. Daclizumab: a review of its use in the prevention of acute rejection in renal transplant recipients. Wiseman LR; Faulds D Drugs; 1999 Dec; 58(6):1029-42. PubMed ID: 10651389 [TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics, pharmacodynamics, and immunodynamics of daclizumab in a two-dose regimen in liver transplantation. Koch M; Niemeyer G; Patel I; Light S; Nashan B Transplantation; 2002 May; 73(10):1640-6. PubMed ID: 12042653 [TBL] [Abstract][Full Text] [Related]
15. Population pharmacokinetics and exposure-response relationships for basiliximab in kidney transplantation. The U.S. Simulect Renal Transplant Study Group. Kovarik JM; Kahan BD; Rajagopalan PR; Bennett W; Mulloy LL; Gerbeau C; Hall ML Transplantation; 1999 Nov; 68(9):1288-94. PubMed ID: 10573065 [TBL] [Abstract][Full Text] [Related]
16. Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. CHIB 201 International Study Group. Nashan B; Moore R; Amlot P; Schmidt AG; Abeywickrama K; Soulillou JP Lancet; 1997 Oct; 350(9086):1193-8. PubMed ID: 9652559 [TBL] [Abstract][Full Text] [Related]
17. Prevention of acute allograft rejection in nonhuman primate lung transplant recipients: induction with chimeric anti-interleukin-2 receptor monoclonal antibody improves the tolerability and potentiates the immunosuppressive activity of a regimen using low doses of both microemulsion cyclosporine and 40-O-(2-hydroxyethyl)-rapamycin. Hausen B; Gummert J; Berry GJ; Christians U; Serkova N; Ikonen T; Hook L; Legay F; Schuler W; Schreier MH; Morris RE Transplantation; 2000 Feb; 69(4):488-96. PubMed ID: 10708100 [TBL] [Abstract][Full Text] [Related]
18. Murine OKT4A immunosuppression in cadaver donor renal allograft recipients: a Cooperative Clinical Trials in Transplantation pilot study. Transplantation; 1997 Apr; 63(8):1087-95. PubMed ID: 9133469 [TBL] [Abstract][Full Text] [Related]
19. Reduction of acute renal allograft rejection by daclizumab. Daclizumab Double Therapy Study Group. Nashan B; Light S; Hardie IR; Lin A; Johnson JR Transplantation; 1999 Jan; 67(1):110-5. PubMed ID: 9921806 [TBL] [Abstract][Full Text] [Related]